XML 77 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Jun. 17, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Numerator          
Consolidated net income $ 1,077,069 $ 624,885 $ 230,064 $ 1,241,201 $ 1,701,954
Less: net income attributable to Continuing Investors Partnerships prior to the IPO         479,842
Less: net income attributable to non-controlling interest     187,232 621,473 726,914
Net income attributable to Royalty Pharma plc - basic and diluted     42,832 619,728 495,198
Net income attributable to Royalty Pharma plc - basic and diluted     $ 42,832 $ 619,728 $ 495,198
Denominator          
Weighted average Class A ordinary shares outstanding - basic (in shares) [1]     437,963 414,794 375,444
Add: Dilutive effect of unvested RSUs (in shares)     9 8 11
Weighted average Class A ordinary shares outstanding - diluted (in shares) [1]     437,972 414,802 375,455
Earnings per Class A ordinary share - basic (in dollars per share) [1]     $ 0.10 $ 1.49 $ 1.32
Earnings per Class A ordinary share - diluted (in dollars per share) [1]     $ 0.10 $ 1.49 $ 1.32
Continuing Investors Partnerships          
Numerator          
Less: net income attributable to non-controlling interest     $ 23,775 $ 297,321  
Legacy Investors Partnerships and RPSFT          
Numerator          
Less: net income attributable to non-controlling interest     $ 163,457 $ 324,152 $ 409,921
Class B Holders          
Numerator          
Less: net income attributable to non-controlling interest         $ 316,993
[1] In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”). See Note 13–Earnings per Share.